| scholarly article | Q13442814 |
| P2093 | author name string | K Totpal | |
| M Ultsch | |||
| P Y Wong | |||
| Y G Meng | |||
| M G Mulkerrin | |||
| L G Presta | |||
| H Gazzano-Santoro | |||
| E E Idusogie | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| rituximab | Q412323 | ||
| P304 | page(s) | 4178-84 | |
| P577 | publication date | 2000-04-15 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc | |
| P478 | volume | 164 |
| Q38827226 | A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. |
| Q35886917 | A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface |
| Q53645990 | A mutant human IgG molecule with only one C1q binding site can activate complement and induce lysis of target cells. |
| Q41603684 | A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. |
| Q33216519 | A new ligand for immunoglobulin g subdomains by screening of a synthetic peptide library |
| Q34322432 | A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus. |
| Q58765419 | A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle |
| Q41593902 | A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice |
| Q30418884 | A rheumatoid factor paradox: inhibition of rituximab effector function |
| Q64063666 | A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress |
| Q28817608 | Advances in Antibody Design |
| Q28079016 | Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life |
| Q30838510 | Affinity polymers tailored for the protein A binding site of immunoglobulin G proteins |
| Q50970050 | An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability. |
| Q27685255 | An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations |
| Q37088489 | Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas |
| Q39422339 | Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells |
| Q46161882 | Antibodies inhibit prion propagation and clear cell cultures of prion infectivity |
| Q35109771 | Antibody therapy of non-Hodgkin's B-cell lymphoma |
| Q90107838 | Antibody-mediated complement activation in pathology and protection |
| Q36213431 | Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma |
| Q52676418 | Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column. |
| Q99711562 | Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains |
| Q37738620 | Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma |
| Q37244715 | Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma |
| Q41899785 | Binding site on human immunoglobulin G for the affinity ligand HWRGWV. |
| Q31082210 | Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn |
| Q44773537 | CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma |
| Q55262155 | CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to Multivalent Antigens and Enhances Hemagglutination. |
| Q64989947 | CH2 domain orientation of human immunoglobulin G in solution: Structural comparison of glycosylated and aglycosylated Fc regions using small-angle X-ray scattering. |
| Q37998496 | Candidate antibody-based therapeutics against HIV-1. |
| Q34516987 | Carbamylation of immunoglobulin abrogates activation of the classical complement pathway |
| Q36079223 | Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention |
| Q40812107 | Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells |
| Q92669076 | Characterization of IgG1 Fc Deamidation at Asparagine 325 and Its Impact on Antibody-dependent Cell-mediated Cytotoxicity and FcγRIIIa Binding |
| Q30344134 | Characterizing biological products and assessing comparability following manufacturing changes. |
| Q30408207 | Community-wide assessment of protein-interface modeling suggests improvements to design methodology |
| Q46955960 | Complement C1q-target proteins recognition is inhibited by electric moment effectors. |
| Q64058164 | Complement C4 Prevents Viral Infection through Capsid Inactivation |
| Q27485131 | Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner |
| Q56656130 | Complement and cellular cytotoxicity in antibody therapy of cancer |
| Q37859539 | Complement and non-complement activating functions of C1q: a prototypical innate immune molecule |
| Q90300290 | Complement in malaria immunity and vaccines |
| Q36899812 | Computationally Designed Bispecific Antibodies using Negative State Repertoires |
| Q64928870 | Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. |
| Q27684440 | Crystal structure of deglycosylated human IgG4-Fc |
| Q27704307 | Crystal structure of human dendritic cell inhibitory receptor C-type lectin domain reveals the binding mode with N-glycan |
| Q21092776 | Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging |
| Q38057713 | Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates |
| Q30596999 | Deciphering the fine details of c1 assembly and activation mechanisms: "mission impossible"? |
| Q89866273 | Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation |
| Q92940332 | DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing |
| Q90212053 | Dynamic Views of the Fc Region of Immunoglobulin G Provided by Experimental and Computational Observations |
| Q30357905 | Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. |
| Q33870167 | Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 |
| Q46330101 | Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice |
| Q36729822 | Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. |
| Q33733443 | Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions |
| Q34424958 | Engineered antibody Fc variants with enhanced effector function |
| Q90107901 | Engineering a human IgG2 antibody stable at low pH |
| Q50048248 | Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability |
| Q91741458 | Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease |
| Q47820029 | Engineering therapeutic monoclonal antibodies |
| Q47225780 | Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15. |
| Q33911461 | Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. |
| Q58724935 | Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies |
| Q52842814 | Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. |
| Q34550963 | Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds |
| Q38883267 | Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions |
| Q33766365 | Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity |
| Q36912134 | FcRn: the neonatal Fc receptor comes of age. |
| Q38040103 | Function and 3D structure of the N-glycans on glycoproteins |
| Q98735454 | Functional and Structural Characterization of a Potent C1q Inhibitor Targeting the Classical Pathway of the Complement System |
| Q42280832 | Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization |
| Q27485481 | Genetically delivered antibody protects against West Nile virus |
| Q36132495 | Glycosylation of recombinant antibody therapeutics |
| Q46117208 | High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. |
| Q39690283 | Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. |
| Q28389577 | Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP |
| Q34087555 | Hotspot-centric de novo design of protein binders |
| Q60647750 | Human IgG1 antibodies suppress angiogenesis in a target-independent manner |
| Q26779758 | Human IgG4: a structural perspective |
| Q38730371 | IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions |
| Q47593242 | IgG Fc engineering to modulate antibody effector functions |
| Q49816574 | IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development. |
| Q34368678 | IgG subclasses and allotypes: from structure to effector functions |
| Q42957185 | IgG2m4, an engineered antibody isotype with reduced Fc function |
| Q26770244 | IgG4 Characteristics and Functions in Cancer Immunity |
| Q28069362 | Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies |
| Q38762019 | Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy. |
| Q37403194 | Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC |
| Q28208361 | Improving the efficacy of antibody-based cancer therapies |
| Q38847426 | Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. |
| Q37417488 | Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains |
| Q80103496 | Interactions between mouse IgG2 antibodies are common and mediated by plasma C1q |
| Q35671707 | Interactions of immunoglobulins outside the antigen-combining site |
| Q30835165 | Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity |
| Q27671018 | Lanthanide binding and IgG affinity construct: Potential applications in solution NMR, MRI, and luminescence microscopy |
| Q26849243 | Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics |
| Q59243312 | Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation |
| Q34629343 | Mapping the interactions of dengue virus NS1 protein with human liver proteins using a yeast two-hybrid system: identification of C1q as an interacting partner |
| Q46880051 | Mass spectrometry analysis of in vitro nitration of a recombinant human IgG1 monoclonal antibody |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. |
| Q50133260 | Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding. |
| Q33232455 | Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. |
| Q26825548 | Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases |
| Q38615349 | Mouse and human FcR effector functions |
| Q34754245 | Multivalent artificial opsonin for the recognition and phagocytosis of Gram-positive bacteria by human phagocytes |
| Q90599451 | Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport |
| Q40454744 | Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. |
| Q47626684 | NMR Detection of Semi-Specific Antibody Interactions in Serum Environments. |
| Q41825788 | NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic |
| Q41415137 | NMR-based structural validation of therapeutic antibody produced in Nicotiana benthamiana. |
| Q27652073 | New insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2·1-Å resolution |
| Q40604291 | Optimization of protein-protein docking for predicting Fc-protein interactions. |
| Q37804830 | Optimizing therapeutic antibody function: progress with Fc domain engineering |
| Q82797138 | Porcine IgG: structure, genetics, and evolution |
| Q36452621 | Potent antibody therapeutics by design |
| Q33877190 | Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies |
| Q43070206 | Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. |
| Q35043113 | Principles of tumor immunosurveillance and implications for immunotherapy |
| Q41874342 | Probing antibody internal dynamics with fluorescence anisotropy and molecular dynamics simulations |
| Q36402805 | Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans |
| Q49592680 | Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy |
| Q38163242 | Protein engineering to target complement evasion in cancer |
| Q33580119 | Protein post-translational modifications: In silico prediction tools and molecular modeling |
| Q42174592 | Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities |
| Q90390474 | R409K mutation prevents acid-induced aggregation of human IgG4 |
| Q47147171 | Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding |
| Q92475901 | Rapid global characterization of immunoglobulin G1 following oxidative stress |
| Q37822354 | Recombinant antibodies: engineering and production in yeast and bacterial hosts |
| Q38957490 | Regulation of antibody effector functions through IgG Fc N-glycosylation |
| Q30428551 | Restricted N-glycan conformational space in the PDB and its implication in glycan structure modeling |
| Q36102906 | Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors |
| Q41231700 | Room temperature structure of human IgG4-Fc from crystals analysed in situ |
| Q46702724 | SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies |
| Q37379764 | Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies |
| Q37468539 | Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies |
| Q36266469 | Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity |
| Q39654732 | Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure. |
| Q35526950 | Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar |
| Q36156532 | Solution conformation of wild-type and mutant IgG3 and IgG4 immunoglobulins using crystallohydrodynamics: possible implications for complement activation |
| Q27680566 | Structural Determinants of Unique Properties of Human IgG4-Fc |
| Q38615376 | Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. |
| Q50520171 | Structural analysis of effector functions related motifs, complement activation and hemagglutinating activities in Lama glama heavy chain antibodies. |
| Q35896873 | Structural and functional anatomy of the globular domain of complement protein C1q. |
| Q40388373 | Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. |
| Q27650876 | Structural characterization of a human Fc fragment engineered for lack of effector functions |
| Q47445247 | Structural characterization of the Man5 glycoform of human IgG3 Fc. |
| Q43244304 | Structural difference in the complement activation site of human IgG1 and IgG3. |
| Q26779753 | TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity |
| Q36105050 | Tailor-made antibody therapeutics |
| Q90299989 | Targets and Antibody Formats for Immunotherapy of Neuroblastoma |
| Q30363006 | The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity |
| Q53163397 | The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases. |
| Q24320322 | The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties |
| Q40017444 | The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies |
| Q35525404 | The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab |
| Q28257521 | The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy |
| Q34307569 | The role of carbohydrate in the assembly and function of polymeric IgG. |
| Q30456830 | The role of complement in mAb-based therapies of cancer |
| Q35221593 | The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands. |
| Q37789831 | The state of antibody therapy |
| Q39966848 | Therapeutic Antibody-Induced Vascular Toxicity Due to Off-Target Activation of Nitric Oxide in Cynomolgus Monkeys. |
| Q37736260 | Therapeutic antibodies for autoimmunity and inflammation |
| Q39664583 | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer |
| Q41924939 | TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery |
| Q41935347 | Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation |
| Q30402428 | Using PyMOL to Explore the Effects of pH on Noncovalent Interactions between Immunoglobulin G and Protein A: A Guided-Inquiry Biochemistry Activity |
Search more.